Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinosarcoma 2Brain Neoplasms 2Wilms Tumor 1Stage I Mixed Cell Type Kidney Wilms Tumor 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Recurrence 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Intraductal Neoplasms 1Ovarian Neoplasms 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Lung Neoplasms 1Locally Advanced Cervical Adenocarcinoma 1Liposarcoma 1Histiocytoma, Malignant Fibrous 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Burkitt Lymphoma 1Barrett Esophagus 1Anus Neoplasms 1Anal Canal Carcinoma 1Adenoma, Islet Cell 1

Interventions

Doxorubicin 8Ifosfamide 6Radiotherapy 4Filgrastim 2pembrolizumab 1pegfilgrastim 1olaratumab 1indolepropanol phosphate 1brigimadlin 1X-Rays 1Watchful Waiting 1Specimen Handling 1Radiotherapy, Conformal 1Observation 1Gemcitabine 1Etoposide 1Docetaxel 1Diathermy 1Combined Modality Therapy 1Chemotherapy, Adjuvant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Histiocytoma, Malignant Fibrous × X-Rays × Clear all
NCT06422806 2026-05-26

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

National Cancer Institute (NCI)

Phase 3 Recruiting
365 enrolled
Sarcoma

Liposarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡